CENCORA DL-,01/ US03073E1055 /
10/09/2024 08:08:19 | Chg. +1.00 | Volume | Bid18:46:25 | Ask18:46:25 | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
211.65EUR | +0.47% | 0 Turnover: 0.00 |
215.30Bid Size: 140 | 216.05Ask Size: 140 | 42.48 bill.EUR | - | - |
GlobeNewswire
28/08
Prevent Cancer Annual Gala to celebrate three decades of commitment to cancer prevention and early d...
GlobeNewswire
14/08
Outlook Therapeutics® Reports Financial Results for Third Quarter Fiscal Year 2024 and Provides Corp...
GlobeNewswire
08/07
Outlook Therapeutics® Announces UK MHRA Marketing Authorization of LYTENAVA™ (bevacizumab gamma) for...
GlobeNewswire
28/05
Outlook Therapeutics® Receives European Commission Marketing Authorization for LYTENAVA™ (bevacizuma...
GlobeNewswire
15/05
Outlook Therapeutics® Reports Financial Results for Second Quarter Fiscal Year 2024 and Provides Cor...
GlobeNewswire
13/05
Outlook Therapeutics® Announces UK Submission of Marketing Authorization Application (MAA) for ONS-5...
GlobeNewswire
09/05
Outlook Therapeutics® to Report Financial Results for Second Quarter Fiscal Year 2024 on May 16, 202...
GlobeNewswire
29/04
Outlook Therapeutics® to Present at the Ophthalmology Innovation Summit (OIS) Retina Innovation Show...
GlobeNewswire
17/04
2024 ICCC Program Provides Free Training, Education, and Mentorship to Small Business Owners
GlobeNewswire
22/03
Outlook Therapeutics® Receives European Union Positive CHMP Opinion for ONS-5010 as a Treatment for ...
GlobeNewswire
18/03
Outlook Therapeutics® Announces Closing of Private Placement of up to $159 Million
GlobeNewswire
14/02
Outlook Therapeutics® Reports Financial Results for First Quarter Fiscal Year 2024 and Provides Corp...
GlobeNewswire
23/01
Outlook Therapeutics® Receives FDA Agreement Under Special Protocol Assessment (SPA) for 90 Day Non-...
GlobeNewswire
22/12/2023
Outlook Therapeutics® Reports Financial Results for Fiscal Year 2023 and Reiterates ONS-5010 Clinica...
GlobeNewswire
19/12/2023
Outlook Therapeutics® Submits Special Protocol Assessment (SPA) to FDA for Non-Inferiority Study of ...